Analysis of the characteristics of pharmacotherapy for outpatients with cardiovascular diseases in the Russian Federation based on the results of an online survey of doctors

Background. Morbidity and mortality from cardiovascular diseases in Russia is high. Arterial hypertension is the main risk factor for cardiovascular diseases and mortality. At the same time, mortality is also caused by coronary heart disease. It is important that the course of cardiovascular diseases depends on early diagnosis and the immediate appointment of adequate therapy.

Materials and methods. In this study, 124 physicians were surveyed. In the first part, antihypertensive therapy was studied, the results of a survey of 104 respondents were used. In the second part, we studied the therapy prescribed in the first year to patients after acute coronary syndrome, using responses received from 20 physicians.

Results. Most of the respondents had the specialization of a general practitioner and had sufficient clinical experience (over 20 years). However, a large number of patients received irrational combinations of drugs. Therefore, many patients with arterial hypertension did not reach the target blood pressure levels within the recommended 3 months. Also, respondents often prescribed a combination of acetylsalicylic acid and clopidogrel to patients during the first year after acute coronary syndrome as a double antiplatelet therapy with the proven effectiveness of using ticagrelor. When prescribing statins, most of the surveyed physicians preferred atorvastatin if there was information about the greater effectiveness of rosuvastatin. 35% of respondents prescribe trimetazidine to more than half of patients during the first year after acute coronary syndrome.

1. Boytsov S. A., Balanova Yu. A., Shal'nova S. A. i dr. AArterial hypertension among persons 25-64 years old: prevalence, awareness, treatment and control. Based on ESSE research materials. Kardiovaskulyarnaya terapiya i profilaktika. 2014; 4 (13): 4-14. DOI 10.15829/1728-8800-2014-4-4-14. EDN SLQTRD. (In Russ.)

2. Ford E. S., Ajani U. A., Croft J. B., Critchley J. A., Labarthe D. R., Kottke T. E., Giles W. H., Capewell S. ExplainingthedecreaseinU.S. deathsfromcoronarydisease, 1980-2000. N Engl J Med. 2007; 356 (23): 2388-2398. DOI: 10.1056/NEJMsa053935. PMID: 17554120.

3. Janion M., Kurzawski J. Przebiegkliniczny i rokowanieodległe u pacjentów z powtórnymzawałemserca [Clinical course and long-term prognosis in patients with recurrent myocardial infarction]. Pol Arch Med Wewn. 2000; 103 (1-2): 53-59.

4. Puchin'yan N. F., Dovgalevskiy YA. P., Dolotovskaya P. V., Furman N. V. Adherence to recommended therapy in patients who have suffered acute coronary syndrome and the risk of developing cardiovascular complications within a year after hospitalization. Ratsional'naya farmakoterapiya v kardiologii. 2011; 5 (7): 567-573. EDN OPQEVJ. (In Russ.)

5. Oshchepkova Ye. V., Isayeva L. G. Low adherence of patients with arterial hypertension to treatment: approaches to its improvement. Atmosfera. Novosti kardiologii. 2003; 3: 33-36 (In Russ.)

6. Baglikov A. N., Rafal'skiy V. V. Practice of using antiplatelet agents in the treatment of acute coronary syndrome at the outpatient stage [Text]. Sbornik materialov Moskovskogo mezhdunarodnogo foruma kardiologov, g. Moskva, 2013. P. 24. (In Russ.)

7. Matsuzaki M., Ogihara T., Umemoto S., et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011; 29 (8): 1649-1659. DOI: 10.1097/HJH.0b013e328348345d.

8. Shvets G. I., Povetkin S. V. Pharmacoepidemiological aspects of the adherence of doctors in Orel medical institutions to the prescription of antihypertensive drugs. Ratsional'naya farmakoterapiya v kardiologii. 2008; 1 (4): 6-9. EDN JSGFTH. (In Russ.)

9. Povetkin S. V., Levashova O. V., Gikavyy V. I. i dr. Comparative pharmacoepidemiological assessment of the prescription of antihypertensive drugs in outpatient practice in Kursk and Chisinau. Ratsional'naya farmakoterapiya v kardiologii. 2018; 3 (14): 402-407. DOI 10.20996/1819-6446-2018-14-3-402-407. EDN XTFHXV. (In Russ.)

10. Nedogoda S. V., Sabanov A. V. Achieving target blood pressure in patients with arterial hypertension during antihypertensive therapy in real clinical practice. Rossiyskiy kardiologicheskiy zhurnal. 2018; 11 (23): 100-109. DOI 10.15829/1560-4071-2018-11-100-109. EDN YPHUOD. (In Russ.)

11. Sokolova N. Yu. Adherence to therapy in patients with stable coronary artery disease after various revascularization operations. Kardiologiya i serdechno-sosudistaya khirurgiya. 2019; 1 (12): 25-30. DOI: 10.17116/kardio20191201125. EDN GFJWZR. (In Russ.)

12. Shilov A. M., Mel'nik M. V., Sirotina I. L. Prevention of thrombosis and thromboembolism in therapeutic and surgical diseases. RMZh. 2004; 9: 519. (In Russ.)

13. Dei Cas M., Rizzo J., Scavone M., Femia E., Podda G. M., Bossi E., et al. In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. Sci Rep. 2021; 11 (1): 10370. https://doi.org/10.1038/s41598-021-89671-w.

14. Kedir H.M., Sisay E.A., Abiye A. A. Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review. Int J Gen Med. 2021; 14: 4757-4763. https://doi.org/10.2147/IJGM.S326929.

15. Comparison of the incidence of stent thrombosis with the use of ticagrelor and clopidogrel in patients with acute coronary syndrome: results of a planned analysis of data from participants in the PLATO study (Study of Platelet Inhibition and Patient Outcomes. Evidence-based cardiology (electronic version). 2013; (3): 29-36. Evidence-based Cardiology. 2013; (3): 29-36. (In Russ.)

16. Khomitskaya Yu. V., Averkov O. V., Ruda M. Ya. Long-term observation of approaches to antithrombotic therapy in Russian patients with acute coronary syndrome: an observational study (EPICOR-RUS). Neotlozhnaya kardiologiya. 2017; 2: 23-36. EDN ZBHAFV. (In Russ.)

17. Comparative effectiveness of the lipid-lowering effect of rosuvastatin and atorvastatin in patients with acute coronary syndrome: results of the open randomized clinical trial LUNAR (LimitingUndertreatmentof Lipidsin AcuteCoronarySy. Evidence-based Cardiology (electronic version). 2012; (2): 15-21. Evidence-basedCardiology. 2012; (2): 15-21. (In Russ.)

18. Ciapponi A., Pizarro R., Harrison J. Trimetazidineforstableangina. Cochrane Database Syst Rev. 2005; (4): CD003614. Published 2005 Oct 19. DOI: 10.1002/14651858.CD003614.pub2.

19. Detry J. M., Sellier P., Pennaforte S., Cokkinos D., Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994; 37 (3): 279-288. DOI: 10.1111/j.1365-2125.1994.tb04276.x).

20. Fendrikova A. V., Skibitskiy V. V. Efficacy of the original drug trimetazidine MB in patients with stable coronary heart disease and angina attacks that persist during the use of generic trimetazidine (ETALON study). Kardiovaskulyarnaya terapiya i profilaktika. 2011; 4 (10): 96-100. DOI: 10.15829/1728-8800-2011-4-96-100. EDN NUBZLJ. (In Russ.)